Does TIMP1 deficiency reduce myocardial fibrosis and ameliorate diastolic dysfunction?
TIMP1 promotes myocardial fibrosis via a novel matrix metalloproteinase-independent mechanism involving CD63-Integrin β1 interaction, making it a potential therapeutic target for antifibrosis therapies.
deficiency persistently reduced myocardial fibrosis and ameliorated diastolic dysfunction. This study defines a novel matrix metalloproteinase-independent function of TIMP1 in promoting myocardial fibrosis. As such targeting TIMP1 could prove to be a valuable approach in developing antifibrosis therapies.
Takawale et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: